{"name":"Sherif Mohamed Abd el moneim Soaida, MD","slug":"sherif-mohamed-abd-el-moneim-soaida-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"intravenous saline plus perineural bupivacaine","genericName":"intravenous saline plus perineural bupivacaine","slug":"intravenous-saline-plus-perineural-bupivacaine","indication":"Regional anesthesia and postoperative pain management via perineural nerve blocks","status":"marketed"},{"name":"Perineural Dexamethasone and bupivacaine","genericName":"Perineural Dexamethasone and bupivacaine","slug":"perineural-dexamethasone-and-bupivacaine","indication":"Peripheral nerve blocks for surgical anesthesia and postoperative pain management","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Systemic Dexamethasone plus perineural bupivacaine","genericName":"Systemic Dexamethasone plus perineural bupivacaine","slug":"systemic-dexamethasone-plus-perineural-bupivacaine","indication":"Perineural nerve blocks with adjunctive anti-inflammatory effect (specific indication not clearly defined in available literature)","status":"marketed"}]}],"pipeline":[{"name":"intravenous saline plus perineural bupivacaine","genericName":"intravenous saline plus perineural bupivacaine","slug":"intravenous-saline-plus-perineural-bupivacaine","phase":"marketed","mechanism":"Intravenous saline provides fluid and electrolyte support while perineural bupivacaine blocks nerve conduction locally to provide regional anesthesia and analgesia.","indications":["Regional anesthesia and postoperative pain management via perineural nerve blocks"],"catalyst":""},{"name":"Perineural Dexamethasone and bupivacaine","genericName":"Perineural Dexamethasone and bupivacaine","slug":"perineural-dexamethasone-and-bupivacaine","phase":"marketed","mechanism":"Perineural dexamethasone and bupivacaine combination provides local anesthesia and reduces inflammation at the nerve injection site to prolong anesthetic duration and reduce postoperative pain.","indications":["Peripheral nerve blocks for surgical anesthesia and postoperative pain management","Regional anesthesia adjuvant therapy"],"catalyst":""},{"name":"Systemic Dexamethasone plus perineural bupivacaine","genericName":"Systemic Dexamethasone plus perineural bupivacaine","slug":"systemic-dexamethasone-plus-perineural-bupivacaine","phase":"marketed","mechanism":"Systemic dexamethasone reduces inflammation while perineural bupivacaine provides local anesthetic blockade of nerve conduction at the injection site.","indications":["Perineural nerve blocks with adjunctive anti-inflammatory effect (specific indication not clearly defined in available literature)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}